FRCEM SBA practice questions is a core part of UK Emergency Medicine practice. Patients on disease-modifying antirheumatic drugs (DMARDs) are a daily reality in UK emergency departments. With approximately 700,000 people in the UK living with rheumatoid arthritis, and millions more receiving long-term immunomodulatory therapy for psoriatic arthritis, systemic lupus erythematosus (SLE), ankylosing spondylitis, inflammatory bowel disease, and systemic vasculitis, the probability of encountering a DMARD-related complication on any given shift is not trivial. These drugs modify, suppress, or redirect the immune response in ways that can produce life-threatening toxicities, mask classic signs of sepsis, and create prescribing hazards that the unwary clinician may not immediately recognise. For candidates working through FRCEM Single Best Answer revision, this therapeutic area is examinable at the level of clinical reasoning, not mere pharmacological recall: the exam expects you to navigate a complex presentation and select the single best management decision under diagnostic uncertainty.
FRCEM SBA practice questions: Key Points: DMARDs in the Emergency Department
- All DMARD classes impair host defence to varying degrees; opportunistic infections including Pneumocystis jirovecii pneumonia (PCP), reactivated tuberculosis, and invasive fungal disease must be considered in any febrile patient on biological therapy.
- IL-6 inhibitors (tocilizumab, sarilumab) suppress CRP synthesis and blunt the febrile response, meaning a normal temperature and near-normal CRP do not exclude serious infection in this cohort.
- Methotrexate toxicity is a genuine emergency: bone marrow suppression, mucositis, and pneumonitis can be precipitated by accidental daily dosing, renal impairment, or concurrent NSAID/trimethoprim use. Leucovorin (folinic acid) rescue is time-critical.
- JAK inhibitors (baricitinib, tofacitinib, upadacitinib) carry MHRA warnings for venous thromboembolism, major adverse cardiovascular events, and herpes zoster reactivation.
- Rituximab causes prolonged B-cell depletion lasting six to twelve months; hypogammaglobulinaemia renders patients susceptible to encapsulated organisms and PCP even long after the last infusion.
- Safe prescribing in the ED requires checking the BNF for interactions before administering NSAIDs, trimethoprim, or live vaccines to any patient on a DMARD.
Clinical Context: Why DMARDs Matter in the ED
The DMARD landscape has expanded considerably since NICE approval of tumour necrosis factor inhibitors (TNFi) in the early 2000s. Conventional synthetic DMARDs (csDMARDs) such as methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, and azathioprine have been in use for decades. Biological DMARDs (bDMARDs) targeting TNF-alpha, IL-6, IL-17, IL-23, T-cell co-stimulation, and B-cell surface antigens represent a second generation. Targeted synthetic DMARDs (tsDMARDs), principally the Janus kinase inhibitors (JAKi), are the most recent class and are subject to evolving NICE guidance and ongoing MHRA pharmacovigilance. ED presentations attributable to DMARD toxicity or DMARD-facilitated infection are common and frequently under-recognised, partly because patients may not volunteer their medication history and partly because the clinical phenotype is atypical. The FRCEM SBA syllabus explicitly covers adverse drug reactions and prescribing in high-risk patients, making this a recurrent theme in FRCEM SBA exam questions.
Pathophysiology of Key DMARD Toxicities
Immunosuppression and the Spectrum of Infection Risk
Each DMARD class disrupts immune homeostasis through a distinct mechanism, and the resulting infection risk reflects that mechanism precisely. TNF-alpha is indispensable for granuloma formation; its inhibition by agents such as adalimumab, etanercept, and infliximab dismantles the principal containment strategy for Mycobacterium tuberculosis. Patients on TNFi are estimated to have a three to four-fold increased risk of TB reactivation compared with the background population. Beyond TB, intracellular organisms including Listeria monocytogenes, non-typhoidal Salmonella, Histoplasma capsulatum, and Pneumocystis jirovecii become significant threats. Rituximab, an anti-CD20 monoclonal antibody, depletes B lymphocytes for six to twelve months following a course; the resulting hypogammaglobulinaemia increases susceptibility to encapsulated bacteria (Streptococcus pneumoniae, Haemophilus influenzae) and opportunistic pathogens. Abatacept, which blocks T-cell co-stimulation via CTLA-4-Ig, and belimumab, which targets the B-cell survival factor BAFF, carry additional risks of PCP and other opportunistic infections.
IL-6 Blockade and the Diagnostic Trap
Tocilizumab and sarilumab block the IL-6 receptor. Because IL-6 drives hepatic acute-phase protein synthesis, patients on these agents may present with florid sepsis yet have a CRP that is near-normal or only mildly elevated, and a blunted or absent febrile response. This is not a pharmacological curiosity: it is a patient safety hazard. An ED physician relying on a CRP of 18 mg/L and a temperature of 37.4 degrees Celsius to reassure themselves that a tocilizumab-treated patient is not septic is applying a clinical heuristic that simply does not hold in this population. Procalcitonin may be a more reliable biomarker, though evidence in this specific context remains limited.
Methotrexate Toxicity: Mechanism and Precipitants
Methotrexate (MTX) is a folate antagonist. At the low weekly doses used in rheumatology (typically 7.5 to 25 mg orally or subcutaneously once weekly), its principal mechanism is anti-inflammatory rather than cytotoxic. However, toxicity occurs predictably when the drug accumulates: through renal impairment (MTX is renally cleared), concurrent use of drugs that compete for tubular secretion or reduce renal blood flow (NSAIDs, probenecid), or, most dangerously, accidental daily dosing by the patient who misunderstands their prescription. MTX inhibits dihydrofolate reductase, depleting intracellular tetrahydrofolate and impairing DNA synthesis in rapidly dividing cells. The clinical triad of bone marrow suppression (pancytopenia), mucositis, and hepatotoxicity is the toxic syndrome; pulmonary toxicity (MTX pneumonitis) is an additional, sometimes insidious, complication. The British National Formulary includes a clear warning that trimethoprim and co-trimoxazole must not be co-prescribed with MTX due to additive antifolate toxicity and the risk of fatal pancytopenia.
JAK Inhibitor Safety Signals
JAKi (baricitinib, upadacitinib, tofacitinib) inhibit intracellular JAK-STAT signalling pathways, attenuating the downstream effects of multiple pro-inflammatory cytokines simultaneously. Post-marketing data, including from the ORAL Surveillance trial examining tofacitinib in high-cardiovascular-risk patients, prompted MHRA safety warnings regarding increased rates of venous thromboembolism (VTE), major adverse cardiovascular events (MACE), and serious infection, including herpes zoster reactivation. Any patient on a JAKi presenting with pleuritic chest pain, leg swelling, or erythematous dermatomal rash should prompt appropriate investigation with these risks clearly in mind. These safety signals are precisely the kind of pharmacological nuance that FRCEM SBA practice questions are designed to probe.
ED Assessment and Management
History
A structured medication history is the cornerstone. Ask specifically about the name, dose, and frequency of every DMARD, the date of the last biological infusion or injection, and whether the patient co-prescribes folic acid (the standard adjunct to MTX). Establish whether any new drug has been recently started by the GP or rheumatologist. Ask about sick contacts, recent foreign travel (which may indicate endemic fungal exposure), and whether TB screening was performed before starting biological therapy.
Investigations
A full blood count is mandatory: neutropenia is the haematological emergency requiring the most urgent response. In a patient on MTX with a white cell count below 1.0 x 10^9/L, or any patient on any DMARD with an absolute neutrophil count below 0.5 x 10^9/L, empirical broad-spectrum antibiotics must not be delayed. Renal function and liver function tests will contextualise drug metabolism and may reveal organ toxicity. CRP and procalcitonin should both be requested in patients on IL-6 inhibitors. Chest radiography is indicated for any respiratory presentation; high-resolution CT may be needed to distinguish MTX pneumonitis from infectious pneumonia. Blood cultures, urinalysis, and targeted microbiological sampling should be obtained before antibiotics where this does not cause unacceptable delay.
Methotrexate Toxicity: Management
Stop methotrexate immediately. Initiate leucovorin (folinic acid) rescue: the standard approach is intravenous or intramuscular leucovorin, with dose and frequency guided by the severity of toxicity and, where available, serum MTX levels. Contact haematology and rheumatology urgently. Supportive care includes management of neutropenic sepsis per local protocol, mucositis care, and renal support if required. Do not administer folic acid instead of folinic acid: folic acid requires dihydrofolate reductase for conversion to the active form, which is the very enzyme blocked by MTX. Folinic acid (leucovorin) bypasses this block entirely.
Neutropenic Sepsis
Any patient on a DMARD presenting with fever and neutropenia should be managed according to the neutropenic sepsis pathway. NICE guideline NG51 recommends that empirical antibacterial therapy be started within one hour of presentation in neutropenic patients with a temperature above 38 degrees Celsius or other signs of clinical instability. Piperacillin/tazobactam (Tazocin) is the first-line agent in most UK trusts unless local resistance patterns or allergy dictates otherwise. Antifungal and anti-PCP cover should be considered in patients on rituximab, high-dose steroids, or those with prolonged neutropenia, in line with local microbiology guidance.
How the FRCEM SBA Exam Tests This Topic
Within the RCEM curriculum, DMARD-related presentations map to domains covering pharmacology, toxicology, infectious disease, and safe prescribing. The FRCEM SBA exam will not ask you to list every side effect of adalimumab; it will give you a clinical vignette and demand a management decision. Common stem types include: a patient on tocilizumab who is afebrile with a low CRP but clinically unwell, where the correct answer is to treat as sepsis despite reassuring inflammatory markers; a patient on weekly MTX who has been taking it daily for a week and presents with oral ulceration and a white cell count of 0.8, where the correct answer involves both leucovorin rescue and urgent haematology referral; a patient on a TNFi presenting with cough, night sweats, and upper zone infiltrates, where TB must be the leading differential; and a patient on baricitinib presenting with a painful unilateral vesicular rash, where herpes zoster is the diagnosis and the prescribing trap is avoiding live vaccines. The FRCEM SBA syllabus also expects awareness of drug interactions: trimethoprim with MTX, NSAIDs with MTX, and live vaccines in any immunosuppressed patient are recurring examination themes.
Revision Pearls: High-Yield Facts for FRCEM SBA
- IL-6 inhibitors (tocilizumab, sarilumab) suppress CRP production directly. Do not use a low CRP to exclude sepsis in this group.
- Methotrexate is taken once weekly in rheumatology. Accidental daily dosing is the commonest cause of acute MTX toxicity. Always clarify the dosing schedule.
- Leucovorin (folinic acid) is the correct rescue agent in MTX toxicity. Folic acid is not interchangeable and will not work.
- TNFi carry a specific risk of TB reactivation. Latent TB must be screened for and treated before starting these drugs. A patient presenting with upper zone consolidation or lymphadenopathy on a TNFi should have TB in the leading differential.
- JAKi are associated with VTE and herpes zoster. An MHRA drug safety update should inform your answer whenever a JAKi patient presents with thrombosis or dermatomal rash.
- Rituximab depletes B cells for six to twelve months. A patient who received rituximab nine months ago and presents with pneumonia may still be profoundly immunosuppressed despite having stopped treatment.
- NSAIDs and trimethoprim are dangerous in patients on MTX. Both reduce renal clearance or exert additive antifolate effects, raising MTX to toxic concentrations.
- Live vaccines are absolutely contraindicated in patients on biological DMARDs or high-dose conventional immunosuppression.
Common Pitfalls: Where Candidates Lose Marks
- Accepting a normal CRP or absent fever as reassurance in a patient on tocilizumab or sarilumab.
- Prescribing trimethoprim for a UTI in a patient on methotrexate without recognising the interaction.
- Administering folic acid rather than folinic acid in MTX toxicity.
- Failing to consider opportunistic infections (PCP, TB, invasive Aspergillus) in a patient on a bDMARD with a respiratory presentation.
- Overlooking that rituximab-treated patients may remain B-cell depleted and hypogammaglobulinaemic for up to a year after their last dose.
- Assuming a patient is not immunosuppressed because they are on hydroxychloroquine alone: this is the least immunosuppressive csDMARD, but combinations are common and the full drug list must be reviewed.
- Neglecting to withhold the offending DMARD and seek specialist input urgently in any patient with suspected drug-related haematological toxicity.
How EM Learning Centre Supports Your FRCEM Single Best Answer Revision
Mastering complex pharmacological topics such as DMARD toxicity requires repeated, deliberate practice with well-constructed clinical vignettes that mirror the standard of the actual exam. The EM Learning Centre homepage hosts a comprehensive suite of resources built specifically for UK emergency medicine trainees. Our FRCEM Single Best Answer revision course at EM Learning Centre includes structured lessons on drug toxicology, immunosuppression-related presentations, safe prescribing in high-risk patients, and the full breadth of the RCEM curriculum. Each lesson is followed by exam-standard FRCEM SBA practice questions with detailed explanations that teach you not just the correct answer but the clinical reasoning that will serve you across multiple vignette types. Whether you are building your initial knowledge base or stress-testing it in the final weeks before your FRCEM SBA exam, the platform is designed to improve your performance systematically. Related lessons on the platform, including those covering acute allergy, anaphylactoid reactions, angioedema in the emergency department, hereditary angioedema, and urticaria, provide important parallel reading for any trainee managing patients on biological therapies, given the overlap between infusion reactions, drug-induced angioedema, and primary allergic disease.
References
- National Institute for Health and Care Excellence. Neutropenic sepsis: prevention and management in people with cancer (NG51). 2012. NICE.
- British National Formulary. Methotrexate: interactions and monitoring requirements. BNF via NICE.
- National Institute for Health and Care Excellence. Rheumatoid arthritis in adults: management (NG100). 2018, updated 2023. NICE.
- Royal College of Emergency Medicine. RCEM Curriculum for Emergency Medicine. RCEM.
- Medicines and Healthcare products Regulatory Agency. JAK inhibitors: new measures to minimise risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections, and effects on pregnancy. Drug Safety Update 2023. NHS.
- The BMJ. Biological DMARDs and infection risk in immune-mediated inflammatory diseases: a clinical overview. The BMJ.
